US Most-Favoured-Nation Drug Pricing Push Turns China Into Key Asset Base for Global Pharma
US most-favoured-nation drug pricing reform is moving forward, drawing global pharmaceutical market attention since 2025. As the policy advances, China has become a major asset base for global drugmakers responding to MFN pressure, and Chinese biotechnology companies are recording rising numbers and values of outbound licensing deals.
The United States' most-favoured-nation (MFN) drug pricing policy is moving forward. Since 2025, the implementation of MFN pricing reform and its effects have drawn attention across the global pharmaceutical market.
The number and value of outbound asset licensing (license-out) deals by Chinese biotechnology companies have continued to climb. On August 7, 2025, local time, in Provo, Utah, a pharmacist took medicine from a shelf inside a pharmacy.
Why this event matters
The event has a measured impact on 3 industrys. The strongest current signal is mixed for Pharmaceuticals, with intensity 65/100 and 60% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- mixed
- Intensity
- 65
- Confidence
- 60%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 55
- Confidence
- 55%
- Horizon
- Medium term
Biotechnology
- Direction
- mixed
- Intensity
- 50
- Confidence
- 50%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.